Invivyd (IVVD) Gross Profit (2024 - 2025)
Invivyd (IVVD) posted Gross Profit of $16.1 million for Q4 2025, up 33.44% on a QoQ basis from $12.0 million in Q3 2025, and up 22.69% year-over-year from $13.1 million in Q4 2024.
Invivyd (IVVD) Gross Profit (2024 - 2025) Analysis & Trends
Invivyd's Gross Profit history runs 2 years deep, the most recent figure standing at $16.1 million for Q4 2025.
- Quarterly Gross Profit rose 22.69% year-over-year to $16.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49.7 million (up 109.03% YoY) and the FY2025 annual result came in at $49.7 million, up 109.03% from the prior year.
- Gross Profit was $16.1 million for Q4 2025 at Invivyd, up from $12.0 million in the prior quarter.
- Across five years, Gross Profit topped out at $16.1 million in Q4 2025 and bottomed at $2.2 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Invivyd | 104.10 Mn | -122.59 Mn | 16.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.07 Mn |
| Dec 31, 2025 | 16.07 Mn |
| Sep 30, 2025 | 12.04 Mn |
| Sep 30, 2025 | 12.04 Mn |
| Jun 30, 2025 | 11.10 Mn |
| Jun 30, 2025 | 11.10 Mn |
| Mar 31, 2025 | 10.47 Mn |
| Mar 31, 2025 | 10.47 Mn |
| Dec 31, 2024 | 13.10 Mn |
| Dec 31, 2024 | 13.10 Mn |
| Sep 30, 2024 | 8.49 Mn |
| Sep 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 2.18 Mn |
| Jun 30, 2024 | 2.18 Mn |